IDH2 and central nervous system cancer: Hewitt et al. designed a weakly supervised DL pipeline to predict glioma subtype by utilizing both 2016 and 2021 WHO classification schemes and predicting the core molecular alterations—IDH mutation, 1p19q codeletion, and ATRX mutation (AUC 0.90, 0.79, & 0.87) [16].